Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer Sells 9,136 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer sold 9,136 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $2.18, for a total value of $19,916.48. Following the completion of the transaction, the director now owns 157,629 shares of the company’s stock, valued at $343,631.22. The trade was a 5.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Allogene Therapeutics Stock Down 3.5 %

Shares of Allogene Therapeutics stock traded down $0.08 during trading hours on Tuesday, hitting $2.19. The company’s stock had a trading volume of 1,883,512 shares, compared to its average volume of 2,467,694. The business has a fifty day moving average of $2.59 and a 200 day moving average of $2.59. Allogene Therapeutics, Inc. has a 1-year low of $1.99 and a 1-year high of $5.78. The company has a market capitalization of $459.18 million, a PE ratio of -1.46 and a beta of 0.83.

Analyst Ratings Changes

ALLO has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler dropped their price target on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Institutional Trading of Allogene Therapeutics

Several large investors have recently added to or reduced their stakes in ALLO. The Manufacturers Life Insurance Company raised its stake in shares of Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after purchasing an additional 5,642 shares during the period. Nisa Investment Advisors LLC increased its stake in Allogene Therapeutics by 429.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after buying an additional 8,734 shares during the period. Arizona State Retirement System increased its stake in Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock worth $95,000 after buying an additional 10,855 shares during the period. Private Advisor Group LLC acquired a new position in Allogene Therapeutics in the 3rd quarter worth $34,000. Finally, Federated Hermes Inc. purchased a new position in Allogene Therapeutics in the 2nd quarter valued at about $29,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).